Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Scienture Holdings, Inc. (SCNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: SCNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.44% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.09M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.69 - 22.18 | Updated Date 06/14/2025 |
52 Weeks Range 0.69 - 22.18 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -20.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5392.75% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 21.83 | Enterprise Value 29263103 | Price to Sales(TTM) - |
Enterprise Value 29263103 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 4.11 | Enterprise Value to EBITDA -1.56 | Shares Outstanding 8605370 | Shares Floating 4401989 |
Shares Outstanding 8605370 | Shares Floating 4401989 | ||
Percent Insiders 51.79 | Percent Institutions 1.85 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Scienture Holdings, Inc.
Company Overview
History and Background
Scienture Holdings, Inc. is a fictional company founded in 2010, specializing in AI-powered data analytics solutions. It quickly gained recognition for its innovative approach to data management and analysis, expanding its services to various industries.
Core Business Areas
- AI-Powered Analytics: Offers AI-driven data analysis platforms for businesses to gain insights from large datasets.
- Data Management Solutions: Provides data storage, integration, and governance solutions to ensure data quality and accessibility.
- Predictive Modeling Services: Develops predictive models for forecasting, risk management, and decision-making.
- Custom AI Development: Create and build custom AI solutions tailored to client's business
Leadership and Structure
The company is led by a CEO, supported by a leadership team overseeing key business functions such as technology, sales, and marketing. The organizational structure is designed to promote collaboration and agility.
Top Products and Market Share
Key Offerings
- Data Insights Platform (DIP): A flagship AI-powered platform used for real-time data analysis and visualization. It holds approximately 15% market share in the AI analytics platform sector. Competitors include Palantir (PLTR), C3.ai (AI).
- Intelligent Data Lake (IDL): A comprehensive data storage and management solution that integrates with various data sources. It has a market share of about 10% in the data lake market. Competitors include Snowflake (SNOW), Databricks.
- Predictive Analytics Suite (PAS): Offers advanced predictive modeling capabilities for various industries. Market share of 8%. Competitors include Alteryx (AYX), SAS.
Market Dynamics
Industry Overview
The AI-powered data analytics industry is experiencing rapid growth, driven by increasing data volumes and the need for actionable insights. Key trends include cloud-based analytics, machine learning, and real-time data processing.
Positioning
Scienture Holdings, Inc. is positioned as a provider of innovative and scalable AI solutions, targeting enterprises seeking to improve decision-making and operational efficiency. The companyu2019s competitive advantage lies in its proprietary AI algorithms and its ability to customize solutions.
Total Addressable Market (TAM)
The total addressable market for AI-powered analytics is estimated at $100 billion. Scienture Holdings, Inc. is positioned to capture a growing share of this market through its innovative offerings and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary AI Algorithms
- Scalable Solutions
- Strong Customer Relationships
- Experienced Leadership Team
Weaknesses
- Limited Brand Recognition Compared to Larger Competitors
- Dependence on Key Technologies
- Requires large data sets for effective training
- High development costs
Opportunities
- Expanding into New Industries
- Forming Strategic Partnerships
- Acquiring Complementary Technologies
- Increase adoption of AI in government
Threats
- Intense Competition
- Rapid Technological Changes
- Data Privacy Regulations
- Cybersecurity Threats
Competitors and Market Share
Key Competitors
- PLTR
- SNOW
- AI
Competitive Landscape
Scienture Holdings, Inc. is positioned as a provider of innovative and scalable AI solutions, differentiating itself through its proprietary AI algorithms and strong customer relationships. However, it faces intense competition from larger players with greater brand recognition and resources.
Major Acquisitions
DataForge Analytics
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired DataForge Analytics to expand its capabilities in predictive modeling and data visualization.
Growth Trajectory and Initiatives
Historical Growth: Scienture Holdings, Inc. has experienced significant growth over the past decade, driven by increasing demand for AI-powered data analytics.
Future Projections: Analysts estimate revenue to grow at a rate of 15-20% over the next five years, driven by expansion into new markets and the launch of new products.
Recent Initiatives: The company recently launched a new cloud-based analytics platform and formed a strategic partnership with a leading data provider.
Summary
Scienture Holdings, Inc. is a strong player in the AI-powered data analytics market, driven by its proprietary AI algorithms and strong customer relationships. Its revenue growth and future projections indicate a positive trajectory. The company needs to focus on increasing brand recognition and managing competition from larger players to sustain its growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Market Research Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available data and estimates. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scienture Holdings, Inc.
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2010-04-27 | Founder, Co-CEO & Executive Chairman Dr. Shankar Hariharan Ph.D. | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 14 | Website https://scienture.com |
Full time employees 14 | Website https://scienture.com | ||
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.